Search
Now showing items 21-30 of 32
Assessment of the attitude, awareness and practice of periprocedural warfarin management among health care professional in Qatar. A cross sectional survey
(
Springer
, 2020 , Article)
It is estimated that 10–15% of oral anticoagulant (OAC) patients, would need to hold their OAC for scheduled surgery. Especially for warfarin, this process is complex and requires multi-layer risk assessment and decisions ...
Cost-Benefit Analysis of Genotype-Guided Interruption Days in Warfarin Pre-Procedural Management
(
Elsevier
, 2022 , Article)
Warfarin is commonly used in thromboembolic conditions. Warfarin interruption represents a significant challenge in pre-operative warfarin management as it is associated with major consequences. Genetics polymorphism ...
Warfarin-Rifampin-Gene (WARIF-G) Interaction: A Retrospective, Genetic, Case–Control Study
(
Wiley-Blackwell
, 2023 , Article)
Warfarin is extensively metabolized by cytochrome P450 2C9 (CYP2C9). Concomitant use with the potent CYP2C9 inducer, rifampin, requires close monitoring and dosage adjustments. Although, in theory, warfarin dose increase ...
Anticoagulation clinic drive-up service during COVID-19 pandemic in Qatar
(
Springer
, 2021 , Article)
Coronavirus Disease 2019 (COVID-19) is a pandemic affecting many countries worldwide. Given the increasing incidence especially in elderly and individuals with comorbid conditions, it is advised by health authorities to ...
Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses
(
Elsevier
, 2021 , Article)
The warfarin peri-procedural management in Qatar is predominantly based on bridging (63%), compared to non-bridging. This study sought to perform a first-time cost analysis of current warfarin peri-procedural management ...
Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar
(
Elsevier
, 2021 , Article)
BackgroundPatients having CYP2C19 loss-of-function alleles and receiving clopidogrel are at higher risk of adverse cardiovascular outcomes. Ticagrelor is an effective antiplatelet that is unaffected by the CYP2C19 polymorphism. ...
Genetic and non-genetic factors impact on inr normalization in preprocedural warfarin management
(
Dove Medical Press
, 2021 , Article)
Background: Annually, 10% of warfarin patients will likely need to stop warfarin prior to elective surgery to achieve a baseline international normalization ratio (INR) level (INR ≤ 1.2) at the time of the procedure. This ...
Genetic polymorphism effect on warfarin–rifampin interaction: A case report and review of literature
(
Dove Medical Press
, 2021 , Article)
Warfarin–rifampin interaction has been reported since the 1970s. Due to rifampin’s strong induction of CYP2C9, most cases could not attain the target international normalized ratio (INR) despite warfarin dose escalation. ...
Cisplatin-induced ototoxicity: A novel approach to an ancient problem
(
Lippincott, Williams & Wilkins
, 2023 , Article)
With the scarcity of pharmacological otoprotective agents against cisplatin-induced ototoxicity (CIO), researchers find themselves compelled to look at and navigate all possible strategies to identify ways to prevent CIO. ...
Evaluation of the Validity of SAMe-TT2R2 Score in a Cohort of Venous Thromboembolism Patients Treated With Warfarin
(
SAGE Publications Inc.
, 2020 , Article)
Low SAMe-TT2R2 score of <2 was validated as a predictor of optimum anticoagulation control, reflected by mean time in therapeutic range (TTR) above 65% to 70%, among warfarin-treated atrial fibrillation patients. This study ...